Is BRNS or BYSI more undervalued in 2026?

CirclFi compares Barinthus Biotherapeutics plc (BRNS) and BeyondSpring, Inc. (BYSI) using 13 institutional-grade valuation models. BRNS has a Quality of Company score of 6.0/10 while BYSI scores 3.5/10.

Which is a better buy — BRNS or BYSI?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do BRNS and BYSI valuations compare?

BRNS at $0.68 and BYSI at $1.72 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

BRNS vs BYSI Valuation Comparison 2026 — Intrinsic Value Analysis

BRNS

Biotechnology

Barinthus Biotherapeutics plc

Quality

6.0

out of 10

Value Trap

SAFE

Price

$0.68

Last close

Models

9/13

Active

BYSI

Biotechnology

BeyondSpring, Inc.

Quality

3.5

out of 10

Value Trap

SAFE

Price

$1.72

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	BRNS Fair Value	BRNS Upside	BYSI Fair Value	BYSI Upside
Bayesian DCF	Intrinsic	$0.94	+37.8%	$3.63	+152.2%
Earnings Power Value	Intrinsic	—	—	$0.75	-49.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$0.26	-63.5%	$1.97	+37.1%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for BRNS vs BYSI — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BRNS vs BYSI — Which Stock Is More Undervalued?

BRNS scores higher with a 6.0/10 quality rating vs BYSI's 3.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Barinthus Biotherapeutics plc (BRNS) and BeyondSpring, Inc. (BYSI) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BRNS currently trades at $0.68 with a QOC of 6.0/10, while BYSI trades at $1.72 with a QOC of 3.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).